Acquired and Intrinsic BRAF Inhibitor Resistance in BRAF V600E Mutant Melanoma

Overview

Journal Biochem Pharmacol

Specialties Biochemistry
Pharmacology

Date 2011 Jun 4

PMID 21635872

Citations 86

Authors

Inna V Fedorenko

Kim H T Paraiso

Keiran S M Smalley

Affiliations

Soon will be listed here.

Abstract

The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biology and provided new strategies for the therapeutic management of this deadly disease. Highly potent small molecule inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas harboring activating BRAF V600E mutations and are associated with high levels of response. This commentary article discusses the latest data on the role of mutated BRAF in the development and progression of melanoma as the basis for understanding the mechanism of action of BRAF inhibitors in the preclinical and clinical settings. We further address the issue of BRAF inhibitor resistance and outline the latest insights into the mechanisms of therapeutic escape as well as describing approaches to prevent and abrogate the onset of both intrinsic and acquired drug resistance. It is likely that our evolving understanding of melanoma genetics and signaling will allow for the further personalization of melanoma therapy with the goal of improving clinical responses.

Citing Articles

Neutrophil diversity and function in health and disease.

Zhang F, Xia Y, Su J, Quan F, Zhou H, Li Q Signal Transduct Target Ther. 2024; 9(1):343.

PMID: 39638788 PMC: 11627463. DOI: 10.1038/s41392-024-02049-y.

Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.

Alhaddad H, Ospina O, Khaled M, Ren Y, Vallebuona E, Boozo M Cell Rep Med. 2024; 5(6):101606.

PMID: 38866016 PMC: 11228800. DOI: 10.1016/j.xcrm.2024.101606.

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Falkman L, Sundin A, Skogseid B, Botling J, Bernardo Y, Wallin G Ups J Med Sci. 2024; 129.

PMID: 38716076 PMC: 11075439. DOI: 10.48101/ujms.v129.10660.

A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.

Dachani S, Kaleem M, Mujtaba M, Mahajan N, Ali S, Almutairy A ACS Omega. 2024; 9(9):10030-10048.

PMID: 38463249 PMC: 10918819. DOI: 10.1021/acsomega.3c09780.

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.

Fang R, Xu S, Gong J, Liao Z Onco Targets Ther. 2024; 17:27-31.

PMID: 38283732 PMC: 10821729. DOI: 10.2147/OTT.S448132.

References

Ley R, Balmanno K, Hadfield K, Weston C, Cook S . Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003; 278(21):18811-6. DOI: 10.1074/jbc.M301010200. View

King A, Patrick D, Batorsky R, Ho M, Do H, Zhang S . Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006; 66(23):11100-5. DOI: 10.1158/0008-5472.CAN-06-2554. View

Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga-Kalabis M, Cipolla A . Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18(6):683-95. PMC: 3026446. DOI: 10.1016/j.ccr.2010.11.023. View

Klein R, Aplin A . Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res. 2009; 69(6):2224-33. PMC: 2657934. DOI: 10.1158/0008-5472.CAN-08-3201. View

Jiang C, Lai F, Tay K, Croft A, Rizos H, Becker T . Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 2011; 1:e69. PMC: 3032346. DOI: 10.1038/cddis.2010.48. View

Yauch R, Dijkgraaf G, Alicke B, Januario T, Ahn C, Holcomb T . Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009; 326(5952):572-4. PMC: 5310713. DOI: 10.1126/science.1179386. View

Smalley K . A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer. 2003; 104(5):527-32. DOI: 10.1002/ijc.10978. View

Montagut C, Sharma S, Shioda T, McDermott U, Ulman M, Ulkus L . Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68(12):4853-61. PMC: 2692356. DOI: 10.1158/0008-5472.CAN-07-6787. View

Mcdermott D, Sosman J, Gonzalez R, Hodi F, Linette G, Richards J . Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008; 26(13):2178-85. DOI: 10.1200/JCO.2007.14.8288. View

10.

Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L . Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361(12):1173-8. PMC: 5317279. DOI: 10.1056/NEJMoa0902903. View

11.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

12.

Smalley K, Lioni M, Palma M, Xiao M, Desai B, Egyhazi S . Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008; 7(9):2876-83. PMC: 2651569. DOI: 10.1158/1535-7163.MCT-08-0431. View

13.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D . Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008; 5(6):e120. PMC: 2408611. DOI: 10.1371/journal.pmed.0050120. View

14.

Cartlidge R, Thomas G, Cagnol S, Jong K, Molton S, Finch A . Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 2008; 21(5):534-44. PMC: 4916913. DOI: 10.1111/j.1755-148X.2008.00491.x. View

15.

Hersey P, Smalley K, Weeraratna A, Bosenberg M, Zhang X, Haass N . Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res. 2011; 24(1):e1-15. DOI: 10.1111/j.1755-148X.2010.00811.x. View

16.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

17.

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View

18.

Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C . A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009; 463(7278):191-6. PMC: 3145108. DOI: 10.1038/nature08658. View

19.

Pollock P, Harper U, Hansen K, Yudt L, Stark M, Robbins C . High frequency of BRAF mutations in nevi. Nat Genet. 2002; 33(1):19-20. DOI: 10.1038/ng1054. View

20.

Eisen T, Ahmad T, Flaherty K, Gore M, Kaye S, Marais R . Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95(5):581-6. PMC: 2360687. DOI: 10.1038/sj.bjc.6603291. View